Transient receptor potential channels in Alzheimer's disease

Yamamoto, Shinichiro; Wajima, Takaaki; Hara, Yuji; Nishida, Motohiro; Mori, Yasuo

doi:10.1016/j.bbadis.2007.03.006

Cited by 103 publications

(65 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10,[66][67][68][69][70][71] A DA também é uma desordem neurodegenerativa multifatorial, caracterizada pela degradação de neurônios colinérgicos em muitas áreas do SNC, depósitos extracelulares de oligômeros de p oteí a β-a iloide βA e i t a elula es de p oteí a τ tau , al…”

Section: Doença De Alzheimer (Da)unclassified

The Contribution of Studies with Canabidiol and Synthetic Analogues in the Design of New Drug Candidates for Neuropsychiatric Disorders and Neurodegenerative Diseases

Viegas¹,

Franco²

2017

Rev. Virtual Quim.

View full text Add to dashboard Cite

Abstract:The first documented use of Cannabis for therapeutic purposes is dated from 2300 BC, with indications for the treatment of constipation, gout, beriberi, malaria, rheumatism and menstrual impairment. The search for therapeutic effects of Cannabis has already been pursued by scientists for over 50 years, and in the last 10 years, a new phase studies has started about marijuana constituents, such as Δ 9 -tetrahydrocannabinol (THC, 1) and cannabidiol (CBD, 2) for medicinal application. CBD is present in about 40% in the crude extract of Cannabis sativa, besides other 60 types of cannabinoids and a number of noncannabinoid constituents, accounting for approximately three hundred secondary metabolites. In spite of CBD being a constituent of Cannabis, it is deprived of the typical effects of the plant, differently from THC that induces anxiety and psychotic effects, being its main psychoactive component. Recent studies suggest that CBD could acts as a THC modulator in the brain, exhibiting anxiolytic and/or antipsychotic effects, antagonizing some undesirable effects of THC, as well as contributing with analgesic, antiemetic and antineoplastic, also affecting synapsis plasticity and facilitating neurogenesis. In this context, the scientific literature reinforces the need of advances and more investments in this research field, aiming a better knowledge about endocannabinoid system and the search for new natural and synthetic cannabinoids, supporting their use in the clinics and improving the available therapeutic arsenal for psychiatric and neurodegenerative diseases. Current data from studies dedicated to an improved understanding of its pharmacology and potential therapeutic applications, suggest that CBD and its analogues could play a singular role in the modulation of molecular targets related to central nervous system disorders, making possible the development of innovative, safer and efficient drugs for the treatment of non-responsive patients to the conventional clinics, with significant improvement in life quality and, perhaps, their cure.Keywords: Cannabidiol; cannabinoids; neuropsychiatric disorders; neurodegenerative diseases. ResumoO primeiro uso documentado da Cannabis para fins terapêuticos é datado de aproximadamente 2300 a.C., para o tratamento de constipação, gota, beribéri, malária, reumatismo e problemas menstruais. A busca por efeitos terapêuticos da Cannabis já recebe atenção de cientistas há mais de 50 anos, sendo que nos últimos 10 anos, tem-se observado uma nova fase de estudos acerca dos o po e tes da a o ha, a e e plo do Δ 9 -tetraidrocanabinol (THC, 1) e do canabidiol (CBD, 2) para uso medicinal. O CBD ocorre em cerca de 40% no extrato bruto de Cannabis sativa, além de outros 60 tipos de canabinoides e inúmeros constituintes não-canabinoides, totalizando cerca de 300 metabólitos secundários. O CBD, apesar de ser um constituinte da Cannabis, é desprovido dos efeitos típicos da planta, diferentemente do THC que induz a ansiedade e efeitos psicóticos, sendo o principal ingrediente psico...

show abstract

Section: Doença De Alzheimer (Da)unclassified

The Contribution of Studies with Canabidiol and Synthetic Analogues in the Design of New Drug Candidates for Neuropsychiatric Disorders and Neurodegenerative Diseases

Viegas¹,

Franco²

2017

Rev. Virtual Quim.

View full text Add to dashboard Cite

show abstract

“…The role of TRPC channels in cell death was documented in several pathological conditions [44,45]. Moreover, members of the TRPM subfamily have been invoked as mediators of oxidative stress.…”

Section: Camentioning

confidence: 99%

Ca2+ signaling mechanisms of cell survival and cell death: An introduction

2011

View full text Add to dashboard Cite

“…Mutations in the presenilin genes are linked to the development of early-onset Alzheimer's and transient expression of presenilin mutants (N141I, M239V) along with TRPC6 in human embryonic kidney -293 cells results in a strong inhibition of agonist (1-oleoyl-2-acetyl-sn-glycerol (OAG) and angiotensin II (Ang II)) induced Ca 2+ entry. Interestingly, the loss of function PS mutant D263A augments the activity of TRPC6 [328,329].…”

Section: Alzheimer's Diseasementioning

confidence: 99%

Ion Channels as Drug Targets in Central Nervous System Disorders

Waszkielewicz¹,

Gunia²,

Szkaradek³

et al. 2013

CMC

View full text Add to dashboard Cite

Ion channel targeted drugs have always been related with either the central nervous system (CNS), the peripheral nervous system, or the cardiovascular system. Within the CNS, basic indications of drugs are: sleep disorders, anxiety, epilepsy, pain, etc. However, traditional channel blockers have multiple adverse events, mainly due to low specificity of mechanism of action. Lately, novel ion channel subtypes have been discovered, which gives premises to drug discovery process led towards specific channel subtypes. An example is Na + channels, whose subtypes 1.3 and 1.7-1.9 are responsible for pain, and 1.1 and 1.2 -for epilepsy. Moreover, new drug candidates have been recognized. This review is focusing on ion channels subtypes, which play a significant role in current drug discovery and development process. The knowledge on channel subtypes has developed rapidly, giving new nomenclatures of ion channels. For example, Ca 2+ channels are not any more divided to T, L, N, P/Q, and R, but they are described as Ca v 1.1-Ca v 3.3, with even newer nomenclature 1A-1I and 1S. Moreover, new channels such as P2X1-P2X7, as well as TRPA1-TRPV1 have been discovered, giving premises for new types of analgesic drugs.

show abstract

Transient receptor potential channels in Alzheimer's disease

Cited by 103 publications

References 144 publications

The Contribution of Studies with Canabidiol and Synthetic Analogues in the Design of New Drug Candidates for Neuropsychiatric Disorders and Neurodegenerative Diseases

The Contribution of Studies with Canabidiol and Synthetic Analogues in the Design of New Drug Candidates for Neuropsychiatric Disorders and Neurodegenerative Diseases

Ca2+ signaling mechanisms of cell survival and cell death: An introduction

Ion Channels as Drug Targets in Central Nervous System Disorders

Contact Info

Product

Resources

About